Avelumab and Merkel Cell Carcinoma: What the Evidence Shows

From General Health Guidance to Targeted Exposure Assessment

For decades, public health communication has centered on general wellness principles, emphasizing lifestyle factors such as diet, exercise, and routine screenings. This broad framework has served as the foundation for understanding disease prevention and health maintenance, often focusing on modifiable behaviors and environmental influences. Within this legacy, the role of pharmaceutical interventions has been discussed primarily in terms of therapeutic benefit and risk-benefit profiles for patients. As scientific inquiry deepens, attention has shifted toward specific drug exposures and their potential long-term consequences, particularly in occupational settings. The transition from general health guidance to targeted exposure assessment requires careful consideration of how certain medications may be associated with adverse outcomes in populations with distinct exposure patterns. One such area of emerging focus involves the immune checkpoint inhibitor Avelumab, which is utilized in oncology but has raised questions regarding its relationship to Merkel cell carcinoma development. This pivot from broad health literacy to occupational exposure concern necessitates a neutral examination of the evidence linking Avelumab administration to subsequent Merkel cell carcinoma risk. The following discussion will explore this association without presuming causation, maintaining an academic lens that prioritizes data interpretation over mechanistic speculation. The goal is to bridge general health awareness with specialized pharmacovigilance in occupational contexts.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab was the first therapeutic agent specifically approved for this indication, and its approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). The drug is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and it carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Evaluating the Evidence: Avelumab as Treatment, Not Cause

The mechanistic pathway linking avelumab to MCC is not one of causation but rather of therapeutic action. Avelumab is used to treat MCC by blocking PD-L1, thereby reactivating the immune system to attack cancer cells. However, this immune activation can lead to immune-related adverse events (irAEs), as checkpoint inhibitors including avelumab are known to cause overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that while avelumab is not causally linked to the development of MCC, it can trigger immune-mediated adverse events in treated patients. For patients who become refractory to avelumab, treatment options are limited. In a multicenter study of the prospective skin cancer registry ADOREG, patients with avelumab-refractory MCC were treated with combined ipilimumab and nivolumab, and responses were observed (https://pubmed.ncbi.nlm.nih.gov/36450381/). Similarly, a retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC reported that three out of five patients responded to the combination according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). These findings highlight the need for effective second-line therapies in avelumab-refractory disease.

Risk Context and Communication

Regarding risk considerations, the adequacy of warnings about avelumab and MCC must be evaluated in the context of its approved use. Avelumab is indicated for the treatment of MCC, not as a cause of it. The drug's prescribing information includes warnings about immune-related adverse events, but there is no evidence from the provided sources that avelumab causes MCC. Instead, the evidence consistently describes avelumab as a treatment for MCC. For affected patients, causation-related considerations should focus on the natural history of MCC and the role of immune checkpoint inhibition in managing the disease. The timeline between avelumab exposure and documented harm, such as immune-related adverse events, can vary. In the case of sarcoidosis reactivation, hypercalcaemia occurred during treatment with avelumab and was managed without discontinuation (https://pubmed.ncbi.nlm.nih.gov/31543781/). For avelumab-refractory disease, progression may occur during or after treatment, and the timeline for response to subsequent therapies like ipilimumab plus nivolumab is not specified in the provided evidence. In summary, avelumab is a therapeutic agent for metastatic MCC, not a causative factor. Its mechanism involves immune checkpoint inhibition, which can lead to immune-related adverse events but not to the development of MCC. The evidence supports its efficacy in a subset of patients, while highlighting the challenge of resistance in approximately half of treated individuals. Risk communication should accurately reflect that avelumab is a treatment for MCC, and any adverse events are related to its immunomodulatory effects rather than causation of the disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. It works by blocking PD-L1 to reactivate the immune system against cancer cells. There is no evidence that avelumab causes MCC; rather, it is approved specifically for treating metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the risks associated with avelumab therapy?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, such as hypercalcaemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, these are side effects of treatment, not evidence that the drug causes MCC. The prescribing information includes warnings about irAEs.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.